0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letter |

Effects of Ex Vivo Skin Microbiopsy on Histopathologic Diagnosis in Melanocytic Skin Lesions FREE

Parastoo Banan, MD1; Lynlee L. Lin, BSc1; Duncan Lambie, BDSc, MBBS, FRCPA2; Tarl Prow, BS, MSc, PhD1; H. Peter Soyer, MD, FACD1
[+] Author Affiliations
1Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Queensland, Australia
2Department of Anatomical Pathology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
JAMA Dermatol. 2013;149(9):1107-1109. doi:10.1001/jamadermatol.2013.5020.
Text Size: A A A
Published online

Currently, histopathologic analysis represents the practical reference standard for the diagnosis of melanocytic skin lesions. However, there are limitations particularly related to the morphologic nature of the histopathologic interpretation and the influence of the clinical information on the final diagnosis.1 To provide lesional tissue from melanocytic proliferations for molecular analysis without jeopardizing the conventional histopathologic diagnosis, we invented a miniaturized biopsy device with a total width of 0.35 mm, containing a sample chamber 0.15 mm wide. This device penetrates approximately 250 µm in healthy skin (ie, superficial dermis) to collect approximately 1600 cells.2 This microbiopsy device can be used without local anesthetic, and there is no need for a suture. Our hypothesis is that the minimal skin damage caused by the microbiopsy does not interfere with the subsequent histopathologic diagnosis.

Five patients scheduled for suspicious pigmented lesion removal at the dermatology department of the Princess Alexandra Hospital, a public tertiary hospital in Brisbane, Australia, were recruited. Consent was obtained from all participants with approval from The University of Queensland/Princess Alexandra Hospital Human Research Ethics Committees. Clinical images of the lesions were taken before surgery and immediately after excision. Each excised lesion was bisected, and 5 microbiopsy specimens were applied ex vivo to one of the halved lesions. The microbiopsy site locations were documented, and the specimens were labeled accordingly. All specimens were sectioned in the hospital’s pathology laboratory according to routine protocol.

All sections were examined by a dermatopathologist (D.L.) for the histopathologic diagnosis, with special emphasis on the microbiopsy defect. The mean (SD) size of the microbiopsy defect was 113 (50) µm wide and 146 (37) µm deep (n = 4). These defects are comparable, albeit not identical, to processing artifacts in nonmicrobiopsied specimens ranging from 20 to 2100 µm wide and 70 to 600 µm deep. Histopathologic diagnoses in both halves, while examined separately, were exactly the same in all lesions. Diagnoses included compound nevus, junctional lentiginous nevus, compound dysplastic nevus, junctional dysplastic nevus, and solar lentigo.

From the 5 lesions included in the study, 2 are displayed herein clinically and histopathologically. Patient 1 was an 88-year-old man with a history of metastatic melanoma, who had a deep shave excision of a new nevus identified on his left flank. One of the microbiopsy defects identified within the melanocytic region was 132 × 74 µm in size (Figure 1). The diagnosis was a compound dysplastic nevus. Patient 2 was a 56-year-old woman with history of nonmelanoma skin cancer, who presented with a changing nevus on her left scapula. One of the microbiopsy defects found outside the lesional region was 145 × 201 µm and reached the superficial dermis (Figure 2). Diagnosis of this lesion was junctional lentiginous nevus.

Place holder to copy figure label and caption
Figure 1.
Patient 1

A, Patient 1 clinical photograph; B, excised lesions; and C, microbiopsy sites (white arrows). D, The microbiopsy device with a sample; E, the site of microbiopsy at low magnification; and F, the site at high magnification.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Patient 2

A, Patient 2 clinical photograph; B, excised lesions; and C, microbiopsy sites (white arrows). D, The microbiopsy site at low magnification; and E, the site at high magnification.

Graphic Jump Location

Over the years, many microdevices have been developed to obtain tissue samples,35 but interestingly enough none of these microdevices are specifically engineered for skin lesions. Because of the new exciting developments of targeted molecular therapies in patients with melanoma,6 there is a need for a minimally invasive biopsy device enabling small tissue collection with minimal adverse effects to perform downstream molecular diagnosis of melanocytic skin lesions.

The size of microbiopsy defects measured in this study was comparable to other artifacts more or less commonly seen in routine sectioned specimens. The potential diagnostic difficulties for the dermatopathologist encountered with the histopathologic assessment of a microbiopsied melanocytic skin lesion can easily be overcome by ordering multiple levels. All 5 melanocytic lesions included in this study were not difficult to assess, and therefore the diagnostic process was not hampered by the microbiopsy-induced artifacts; however, on the basis of the size of the microbiopsy artifacts, we foresee that the diagnostic process, even in equivocal cases, will not be influenced. The data from this study support the hypothesis that minimal skin damage caused by the microbiopsy does not affect the histopathologic diagnosis.

Corresponding Author: H. Peter Soyer, MD, FACD, Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute (TRI), 37 Kent St, Woolloongabba, QLD 4102, Australia (p.soyer@uq.edu.au).

Accepted for Publication: May 7, 2013.

Published Online: July 17, 2013. doi:10.1001/jamadermatol.2013.5020.

Author Contributions: All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Lambie, Prow, Soyer.

Acquisition of data: Banan, Lin, Lambie.

Analysis and interpretation of data: All authors.

Drafting of the manuscript: Banan, Lin, Prow.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Banan.

Obtained funding: Soyer.

Administrative, technical, and material support: Banan, Lin, Lambie, Prow.

Study supervision: Lambie, Prow, Soyer.

Conflict of Interest Disclosures: None reported.

Funding/Support: This study was supported in part by Epiderm. Dr Soyer has a National Health and Medical Research Council Practitioner Fellowship.

Ferrara  G, Argenyi  Z, Argenziano  G,  et al.  The influence of clinical information in the histopathologic diagnosis of melanocytic skin neoplasms. PLoS One. 2009;4(4):e5375.
PubMed   |  Link to Article
Lin  LL, Prow  TW, Raphael  AP,  et al.  Microbiopsy engineered for minimally invasive and suture-free sub-millimetre skin sampling. F1000Research. 2013;2:120. doi:10.12688/f1000research.2-120.v1. http://f1000research.com/articles/2-120/v1#reflist. Accessed May 2, 2013.
Cosnier  ML, Martin  F, Bouamrani  A, Berger  F, Caillat  P.  A minimally invasive microdevice for molecular sampling and analysis. IEEE Trans Biomed Eng. 2009;56(12):2898-2904.
PubMed   |  Link to Article
Pflueger DR, inventor; Stryker Puerto Rico Limited, assignee. Micro-invasive breast biopsy device. US patent 6,673,023 B2. January 6, 2004. http://www.google.com/patents/US6673023. Accessed January 16, 2013.
Cho D, Park SK, Lee AR, et al, inventors; Seoul National University Industry Foundation, assignee. Catheter capable of being equipped with micro biopsy tool. US patent 7,927,289 B2. April 19, 2011. http://www.google.com/patents/US7927289. Accessed January 16, 2013.
Khattak  M, Fisher  R, Turajlic  S, Larkin  J.  Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol. 2013;5(2):105-118.
PubMed   |  Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.
Patient 1

A, Patient 1 clinical photograph; B, excised lesions; and C, microbiopsy sites (white arrows). D, The microbiopsy device with a sample; E, the site of microbiopsy at low magnification; and F, the site at high magnification.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Patient 2

A, Patient 2 clinical photograph; B, excised lesions; and C, microbiopsy sites (white arrows). D, The microbiopsy site at low magnification; and E, the site at high magnification.

Graphic Jump Location

Tables

References

Ferrara  G, Argenyi  Z, Argenziano  G,  et al.  The influence of clinical information in the histopathologic diagnosis of melanocytic skin neoplasms. PLoS One. 2009;4(4):e5375.
PubMed   |  Link to Article
Lin  LL, Prow  TW, Raphael  AP,  et al.  Microbiopsy engineered for minimally invasive and suture-free sub-millimetre skin sampling. F1000Research. 2013;2:120. doi:10.12688/f1000research.2-120.v1. http://f1000research.com/articles/2-120/v1#reflist. Accessed May 2, 2013.
Cosnier  ML, Martin  F, Bouamrani  A, Berger  F, Caillat  P.  A minimally invasive microdevice for molecular sampling and analysis. IEEE Trans Biomed Eng. 2009;56(12):2898-2904.
PubMed   |  Link to Article
Pflueger DR, inventor; Stryker Puerto Rico Limited, assignee. Micro-invasive breast biopsy device. US patent 6,673,023 B2. January 6, 2004. http://www.google.com/patents/US6673023. Accessed January 16, 2013.
Cho D, Park SK, Lee AR, et al, inventors; Seoul National University Industry Foundation, assignee. Catheter capable of being equipped with micro biopsy tool. US patent 7,927,289 B2. April 19, 2011. http://www.google.com/patents/US7927289. Accessed January 16, 2013.
Khattak  M, Fisher  R, Turajlic  S, Larkin  J.  Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol. 2013;5(2):105-118.
PubMed   |  Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles